Albany, NY -- (SBWIRE) -- 01/28/2016 -- Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.
Read the full press release at http://www.sbwire.com/press-releases/global-immunology-industry-trend-growth-size-share-and-forecast-to-2022-large-pipeline-and-competitive-market-660852.htm